Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle? (Q42788962)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

editorial

0 references

title

Allopurinol-thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

17 January 2020

main subject

0 references

author

Richard Gearry

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Murray Barclay

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1

Rebecca L Roberts

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

1505-1508

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Observations on the use of allopurinol in combination with azathioprine or mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Trinucleotide repeat variants in the promoter of the thiopurine S-methyltransferase gene of patients exhibiting ultra-high enzyme activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

IMPDH1 promoter mutations in a patient exhibiting azathioprine resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

The role of xanthine oxidase in thiopurine metabolism: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Functional characterization of human xanthine oxidase allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.143

21 January 2018

Identifiers

DOI

10.2217/PGS.10.143

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21121769%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference